Selected Publications

Lee MH, Rapti M and Murphy G. Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumour necrosis factor-α-converting enzyme. J Biol Chem 2005; 280(16): 15967-15975. PubMed

Soond SM, Everson B, Riches DW and Murphy G. ERK-mediated phosphorylation of Thr735 in TNFα-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci 2005; 118: 2371-2380. PubMed

Lee MH, Rapti M, Knäuper V and Murphy G. Threonine-98: the pivotal residue of tissue inhibitor of metalloproteinase (TIMP)-1 in metalloproteinase recognition. J Biol Chem 2004; 279(17): 17562-17569. PubMed

Weskamp G, Schlöndorff J, Lum L, Becherer D, Kim TW, Saftig P, Hartmann D, Murphy G and Blobel CP. Evidence for a critical role of the tumour necrosis factor α convertase(TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75^NTR). J Biol Chem 2004; 279 (6): 4241-4269. PubMed

Remacle A, Murphy G and Roghi C. Membrane Type1-Matrix Metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci 2003; 116: 3905-3916. PubMed

Primary Research Publications

2008

Krubasik D, Eisenach PA, Kunz-Schughart LA, Murphy G, English WR. Granulocyte-macrophage colony stimulating factor induces endothelial capillary formation through induction of membrane-type 1 matrix metalloproteinase expression in vitro. International Journal of Cancer. 2008; 122:1261-72

Puxeddu I, Pang YY, Harvey A, Haitchi HM, Nicholas B, Yoshisue H, Ribatti D, Clough G, Powell RM, Murphy G, Hanley NA, Wilson DI, Howarth PH, Holgate ST, Davies DE. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. Journal of Allergy and Clinical Immunology 2008; 121:1400-6

Saeb-Parsy K, Veerakumarasivam A, Wallard MJ, Thorne N, Kawano Y, Murphy G, Neal DE, Mills IG, Kelly JD. MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3. British Journal of Cancer 2008; 99:663-9

Rapti M, Atkinson SJ, Lee MH, Trim A, Moss M, Murphy G. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. Biochemical Journal 2008; 411:433-9

White K, Buning H, Kritz A, Janicki H, McVey J, Perabo L, Murphy G, Odenthal M, Work LM, Hallek M, Nicklin SA, Baker AH. Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Therapy 2008; 15:443-451

2007

Horiuchi K, Le Gall S, Schulte M, Yamaguchi T, Reiss K, Murphy G, Toyama Y, Hartmann D, Saftig P, Blobel CP. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 2007; 18(1):176-188

Langlois S, Nyalendo C, Di Tomasso G, Labrecque L, Roghi C, Murphy G, Gingras D, Beliveau R. Membrane-type 1 matrix metalloproteinase stimulates cell migration through epidermal growth factor receptor transactivation. Mol Cancer Res 2007; 5(6):569-583

Lee MH, Atkinson S, Murphy G. Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1. J Biol Chem 2007; 282(9):6887-6898

Nyalendo C, Michaud M, Beaulieu E, Roghi C, Murphy G, Gingras D, Beliveau R. Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573 - Role in endothelial and tumor cell migration. J Biol Chem 2007; 282(21):15690-15699

Sithu SD, English WR, Olson P, Krubasik D, Baker AH, Murphy G, D'Souza SE. Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. J Biol Chem 2007; 282(34):25010-25019

Wayne GJ, Deng SJ, Amour A, Borman S, Matico R, Carter HL, Murphy G. TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4. J Biol Chem 2007; 282(29):20991-20998

2006

Atkinson SJ, Roghi C, Murphy G. MT1-MMP hemopexin domain exchange with MT4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF7 cells. Biochem J 2006; 398(Pt 1):15-22

Chabottaux V, Sounni NE, Pennington CJ, English WR, van den Brule F, Blacher S, Gilles C, Munaut C, Maquoi E, Lopez-Otin C, Murphy G, Edwards DR, Foidart JM, Noel A. Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res 2006; 66(10):5165-5172

English JL, Kassiri Z, Koskivirta I, Atkinson SJ, Di Grappa M, Soloway PD, Nagase H, Vuorio E, Murphy G, Khokha R. Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem 2006; 281(15):10337-10346

Krubasik D, Iyer NG, English WR, Ahmed AA, Vias M, Roskelley C, Brenton JD, Caldas C, Murphy G. Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition. Br J Cancer 2006; 94(9):1326-1332

Ohtsuka T, Shiomi T, Shimoda M, Kodama T, Amour A, Murphy G, Ohuchi E, Kobayashi K, Okada Y. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer 2006; 118(2):263-273

Rapti M, Knauper V, Murphy G, Williamson RA. Characterization of the AB loop region of TIMP-2 - Involvement in pro-MMP-2 activation. J Biol Chem 2006; 281(33):23386-23394

Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G, D'Souza SE. Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 2006; 281(6):3157-3164

Tuccinardi T, Martinelli A, Nuti E, Carelli P, Balzano F, Uccello-Barretta G, Murphy G, Rossello A. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Bioorg Med Chem 2006; 14(12):4260-4276

Wallard MJ, Pennington CJ, Veerakumarasivam A, Burtt G, Mills IG, Warren A, Leung HY, Murphy G, Edwards DR, Neal DE, Kelly JD. Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer 2006; 94(4):569-577

2005

Forsyth CB, Cole A, Murphy G, Bienias JL, Im HJ, Loeser RF. Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli. J Gerontol A 2005; 60(9):1118-1124

Langlois S, Di Tomasso G, Boivin D, Roghi C, Murphy G, Gingras D, Beliveau R. Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism. Exp Cell Res 2005; 307(2):452-464

Lee MH, Rapti M, Murphy G. Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting - Fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-alpha-converting enzyme. J Biol Chem 2005; 280(16):15967-15975

Limb GA, Matter K, Murphy G, Cambrey AD, Bishop PN, Morris GE, Khaw PT. Matrix metal loproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol 2005; 166(5):1555-1563

Moller Sorensen N, Dowell BL, Stewart KD, Jensen V, Larsen L, Lademann U, Murphy G, Nielsen HJ, Brunner N, Davis GJ. Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases-1. Tumor Biol 2005; 26(2):71-80

Murphy G, Lee MH. What are the roles of metalloproteinases in cartilage and bone damage? Ann Rheum Dis 2005; 64(Supp 4):44-47

Nisato RE, Hosseini G, Sirrenberg C, Butler GS, Crabbe T, Docherty AJP, Wiesner M, Murphy G, Overall CM, Goodman SL, Pepper MS. Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta(3) in anglogenesis in vitro: Absence of hemopexin c domain bioactivity, but membrane-type 1-MMP and alpha(v)beta(3) are critical. Cancer Res 2005; 65(20):9377-9387

Rossello A, Nuti E, Carelli P, Orlandini E, Macchia M, Nencetti S, Zandomeneghi M, Balzano F, Barretta GU, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A. N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of NIMP-2 and MT1-MMP. Bioorg Med Chem Lett 2005; 15(5):1321-1326

Rossello A, Nuti E, Catalani MP, Carelli P, Orlandini E, Rapposelli S, Tuccinardi T, Atkinson SJ, Murphy G, Balsamo A. A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. Bioorg Med Chem Lett 2005; 15(9):2311-2314

Singh RJR, Mason JC, Lidington EA, Edwards DR, Nuttall RK, Khokha R, Knauper V, Murphy G, Gavrilovic J. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res 2005; 67(1):39-49

Soond SM, Everson B, Riches DWH, Murphy G. ERK-mediated phosphorylation of Thr735 in TNF alpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci 2005; 118(11):2371-2380

2004

Atkinson SJ, English JL, Holway N, Murphy G. Cellular cholesterol regulates MT1 MMP dependent activation of MMP2 via MEK-1 in HT1080 fibrosarcoma cells. FEBS Lett 2004; 566(1-3):65-70

Gottgens B, Broccardo C, Sanchez MJ, Deveaux S, Murphy G, Gothert JR, Kotsopoulou E, Kinston S, Delaney L, Piltz S, Barton LM, Knezevic K, Erber WN, Begley CG, Frampton J, Green AR. The scl +18/19 stem cell enhancer is not required for hematopoiesis: Identification of a 5 ' bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1. Mol Cell Biol 2004; 24(5):1870-1883

Labrecque L, Nyalendo C, Langlois S, Durocher Y, Roghi C, Murphy G, Gingras D, Beliveau R. Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem 2004; 279(50):52132-52140

Lee MH, Rapti M, Knauper V, Murphy G. Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. J Biol Chem 2004; 279(17):17562-17569

Lee MH, Rapti M, Murphy G. Delineating the molecular basis of the inactivity of tissue inhibitor of metalloproteinase-2 against tumor necrosis factor-alpha-converting enzyme. J Biol Chem 2004; 279(43):45121-45129

Rasmussen FH, Yeung N, Kiefer L, Murphy G, Lopez-Otin C, Vitek MP, Moss ML. Use of a multiple-enzyme/multiple-reagent assay system to quantify activity levels in samples containing mixtures of matrix metalloproteinases. Biochemistry 2004; 43(11):2987-2995

Rossello A, Nuti E, Orlandini E, Carelli P, Rapposelli S, Macchia M, Minutolo F, Carbonaro L, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg Med Chem 2004; 12(9):2441-2450

Sounni NE, Roghi C, Chabottaux V, Janssen M, Munaut C, Maquoi E, Galvez BG, Gilles C, Frankenne F, Murphy G, Foidart JM, Noel AS. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 2004; 279(14):13564-13574

Weskamp G, Schlondorff J, Lum L, Becherer JD, Kim TW, Saftig P, Hartmann D, Murphy G, Blobel CP. Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75(NTR)). J Biol Chem 2004; 279(6):4241-4249

2003

Lee MH, Dodds P, Verma V, Maskos K, Knauper V, Murphy G. Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme. Biochem J 2003; 371(Pt 2):369-376

Lee MH, Rapti M, Murphy G. Unveiling the surface Epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase. J Biol Chem 2003; 278(41):40224-40230

Murphy G, Knauper V, Lee MH, Amour A, Worley JR, Hutton M, Atkinson S, Rapti M, Williamson R. Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. Biochem Soc Symp 2003; 70:65-80

Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9(4):407-415

Remacle A, Murphy G, Roghi C. Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci 2003; 116(19):3905-3916

Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, Foekens JA, Brunner N, Holten-Andersen MN. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2003; 2(3):164-172

Worley JR, Thompkins PB, Lee MH, Hutton M, Soloway P, Edwards DR, Murphy G, Knauper V. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochem J 2003; 372(Pt 3):799-809

2002

Amour A, Knight CG, English WR, Webster A, Slocombe PM, Knauper V, Docherty AJP, Becherer JD, Blobel CP, Murphy G. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett 2002; 524(1-3):154-158

Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115(19):3719-3727

Bond M, Murphy G, Bennett MR, Newby AC, Baker AH. Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem 2002; 277(16):13787-13795

Knauper V, Bailey L, Worley JR, Soloway P, Patterson ML, Murphy G. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett 2002; 532(1-2):127-130

Lee MH, Maskos K, Knauper V, Dodds P, Murphy G. Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: A new frontier in TIMP engineering. Protein Sci 2002; 11(10):2493-2503

Other Publications

Murphy G. The ADAMs family: signalling scissors of the tumour microenvironment. Nature Reviews Cancer 2008; 8:932-41

Murphy G. Regulation of the proteolytic disintegrin metalloproteinases, the 'Sheddases'. Seminars in Cell and Developmental Biology. 2008; Sep 18 [E-pub ahead of print]

Murphy G, Murthy A, Khokha R. Clipping, shedding and RIPping keep immunity on cue. Trends in Immunology 2008; 29:75-82

Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nature Clinical Practice Rheumatology. 2008; 4:128-35

Murphy G, Nagase H. Progress in matrix metalloproteinase research. Molecular Aspects of Medicine 2008; 5:290-308

Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69(3):562-573

Holgate ST, Davies DE, Rorke S, Cakebread J, Murphy G, Powell RM, Holloway JW. ADAM 33 and its association with airway remodeling and hyperresponsiveness in asthma. Clin Rev Allergy Immunol 2004; 27(1):23-34

Lee MH, Murphy G. Matrix metalloproteinases at a glance. J Cell Sci 2004; 117(18):4015-+